Ron Bradfield

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Pharmaceutical companies are facing several major interrelated challenges, the most strategic being the decline in R&D productivity resulting in empty product pipelines to replace products nearing patent expiry. A common response has been mergers and acquisition of competitors and biotechnology firms, but rather than resolving the problems, this has created(More)
  • 1